Five reasons to invest in GAVI - I CARE

GAVI needs US$ 3.7 billion to avert four million future deaths by 2015. Here are five reasons why investing in vaccines and immunisation through our Alliance guarantees a high rate of return in lives and dollars

Impact

Four million future deaths can be averted by 2015 through increased investment in vaccines

GAVI's first decade has averted over five million future deaths. With US$ 3.7 billion through to 2015, GAVI has the potential to immunise 240 million children and avert an additional four million future deaths with its support for a series of life-saving vaccines that have yet to reach the world's poorest countries. The new offensive will target:

the two biggest killers of children, pneumonia and diarrhoea, through accelerating the introduction of pneumococcal and rotavirus vaccines;
deadly meningitis epidemics supporting a new vaccine against meningitis A;
the introduction of Human papillomavirus (HPV) vaccines that protect women against cervical cancer, and other prioritised vaccines against Japanese encephalitis, rubella and typhoid;
strengthened routine immunisation programmes as part of integrated health services for women and children.

Compassion

The world cannot afford to miss the opportunity to deliver life-saving vaccines against the two biggest child killers

Everything is in place for GAVI to protect children from pneumonia and diarrhoea and help the world move toward achieving Millennium Development Goal four - reducing child mortality by two-thirds before 2015:

GAVI's programme support offers new and life-saving vaccines against pneumococcal and rotavirus disease;
Immunisation coverage in low-income countries is 79%, ensuring the new vaccines will reach many of even the most remote communities;
Demand in developing countries is high with 45 GAVI-eligible countries ready to offer pneumococcal vaccines, 33 planning to introduce rotavirus vaccines.

Accountability

GAVI support counts 100% towards G8 mother-child health commitments

In June 2010, the G8 reviewed the programmes of all major multilateral agencies to calculate how much core contributions to these agencies would impact on the Muskoka Initiative for Maternal, Newborn and Child Health. They concluded that donor investments in GAVI would count 100%.

Expanded immunisation coverage for children was ranked among the top five most cost-effective solutions to major global challenges by Copenhagen Consensus (2008), an international think tank.

Right to health

Poor children have the same right to access life-saving vaccines as children from wealthier backgrounds

Yet, on average, 15 years separate a vaccine's discovery and its introduction in low-income countries. This means 23.2 million of all children do not receive the life-saving vaccines that are taken for granted on vaccination cards in most industralised countries. Investing in GAVI and vaccines will help redress this inequity.

Effectiveness

The United Kingdom Multilateral Aid Review 2011 places GAVI at the top of multilateral development organisations for value for money, organisational strengths and contribution to development

The GAVI business model fosters a competitive vaccine market by pooling demand from developing countries and providing predictable financing to meet demand, attracting new manufacturers from emerging economies and increasing competition to drive down prices;

GAVI's co-financing scheme has increased country ownership of its support programmes;
GAVI support is aligned with national immunisation and health plans in line with the principles of aid effectiveness; the Health Systems Funding Platform is harmonising health system support;
GAVI's success is driven by an inclusive partnership with the key stakeholders in global immunisation;
GAVI has pioneered new ways of financing development: the International Finance Facility for Immunisation (IFFIm) leverages long-term donor commitments to issue bonds on the capital markets, contributing to the certainty of funding that underpins long-term vaccine programmes; the pneumococcal Advance Market Commitment (AMC) has accelerated the introduction of pneumococcal vaccines in developing countries within months of their introduction in industrialised countries and at lower prices.